Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial

American Journal of Medicine

Volumn 103, Issue 6, 1997, Pages 491-497

  Garber, Alan J ^a   Duncan, Theodore G ^b   Goodman, Anita M ^c   Mills, Donna J ^d   Rohlf, Jane L ^d,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c Lipha Pharmaceuticals Inc   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031472452     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00254-4     Document Type: Article

References (31)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 329:1993;977-986.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 28:1995;103-117.
3. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr. Diabetes. 36:1987;523-534.
4. Johnson AB, Webster JM, Sum C-F, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 42:1993;1217-1222.
5. Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care. 10:1987;62-67.
6. Hother-Nielsen O, Schmitz O, Andersen PH, et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol. 120:1989;257-265.
7. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care. 13:1990;696-704.
8. Widén EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes. 41:1992;354-358.
9. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 73:1991;1294-1301.
10. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Diabetes. 43:1994;920-928.
11. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 15:1992;755-772.
12. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl. 15:1985;105-111.
13. Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab. 74:1992;1020-1026.
14. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ. 310:1995;83-88.
15. Nagi DK, Yudkin J. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 16:1993;621-629.
16. Azerad E, Lubetzki J. The treatment of adult diabetes with N-N dimethyl-diguanide (LA 6023). Bull Soc Med Hop (Paris). 3-4:1959;132-136.
17. Azerad E. The treatment of adult diabetes with N-N dimethyl-diguanide. Union Med Can. 92:1963;1251-1259.
18. Leblanc D. Contribution to the study of a synthetic hypoglycemic: NN dimethyl biguanide hydrochloride. Thesis Med. 1960;1-64.
19. Duval D. Contribution to the study of the hypoglycemic action of biguanides. Thesis Pharm. 1960;77-109.
20. Sterne J. Toxicology of the antidiabetic biguanides. Dimethylguanylguanide hydrochloride. 4th IDF Congress, Geneva, Switzerland. 1961;July 10-14:712-716.
21. Sterne J, Duval D. Hypoglycemic effects of N-N-dimethylbiguanide. 3rd IDF Congress, Dûsseldorf, Germany. 1958:July 21-25:443-452.
22. Williams DA. The comparison of several dose levels with a zero dose control. Biometrics. 28:1972;519-531.
23. Glucophage® (metformin hydrochloride tablets) 500 mg and 850 mg. Prescribing information. February 1995;Bristol-Myers Squibb Company, Princeton, New Jersey.
24. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 19:1996;64-66.
25. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. NEJM. 333:1995;541-549.
26. Goldberg RB, Holvey SM, Schneider J. The Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 19:1996;849-856.
27. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care. 18:1995;817-824.
28. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 19:1996;151-156.
29. Stenman S, Melander A, Groop P-H, Groop L. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med. 118:1993;169-172.
30. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab (Paris). 5:1979;233-245.
31. Bailey CJ, Turner RC. Metformin. NEJM. 334:1996;574-579.